BRPI0416240A - usos de um ou vários agonistas de famìlia de receptores de receptores de formil peptìdeo e semelhante a receptores de formil peptìdeo, composições farmecêuticas para evitar ou tratar infecções virais ou retro-virais, e, método para favorecer a resistência inata de hospedeiros a infecções virais - Google Patents

usos de um ou vários agonistas de famìlia de receptores de receptores de formil peptìdeo e semelhante a receptores de formil peptìdeo, composições farmecêuticas para evitar ou tratar infecções virais ou retro-virais, e, método para favorecer a resistência inata de hospedeiros a infecções virais

Info

Publication number
BRPI0416240A
BRPI0416240A BRPI0416240-4A BRPI0416240A BRPI0416240A BR PI0416240 A BRPI0416240 A BR PI0416240A BR PI0416240 A BRPI0416240 A BR PI0416240A BR PI0416240 A BRPI0416240 A BR PI0416240A
Authority
BR
Brazil
Prior art keywords
formyl peptide
infections
peptide receptor
viral
hosts
Prior art date
Application number
BRPI0416240-4A
Other languages
English (en)
Inventor
Francisco Veas
Dorothee Misse
Mario Clerici
Daria Trabatoni
Original Assignee
Inst Rech Developpement Ird
Immuniclin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Rech Developpement Ird, Immuniclin Ltd filed Critical Inst Rech Developpement Ird
Publication of BRPI0416240A publication Critical patent/BRPI0416240A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1716—Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

"USOS DE UM OU VáRIOS AGONISTAS DE FAMìLIA DE RECEPTORES DE RECEPTORES DE FORMIL PEPTìDEO E SEMELHANTE A RECEPTORES DE FORMIL PEPTìDEO, COMPOSIçõES FARMACêUTICAS PARA EVITAR OU TRATAR INFECçõES VIRAIS OU RETRO-VIRAIS, E, MéTODO PARA FAVORECER A RESISTêNCIA INATA DE HOSPEDEIROS A INFECçõES VIRAIS". A invenção refere-se ao uso como biomarcadores de resistência a infecção em humanos de um ou vários agonistas de família de receptores de receptores de formil peptídeo (FPR) e semelhante a receptores de formil peptídeo (FPRL1). Os referidos biomarcadores são utilizáveis no diagnóstico, profilaxia e terapêuticas.
BRPI0416240-4A 2003-11-05 2004-11-05 usos de um ou vários agonistas de famìlia de receptores de receptores de formil peptìdeo e semelhante a receptores de formil peptìdeo, composições farmecêuticas para evitar ou tratar infecções virais ou retro-virais, e, método para favorecer a resistência inata de hospedeiros a infecções virais BRPI0416240A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51710403P 2003-11-05 2003-11-05
US58072004P 2004-06-21 2004-06-21
PCT/EP2004/013393 WO2005044292A2 (en) 2003-11-05 2004-11-05 Biomarkers of resistance to hiv-infections in humans and biological applications thereof

Publications (1)

Publication Number Publication Date
BRPI0416240A true BRPI0416240A (pt) 2007-01-09

Family

ID=34576787

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416240-4A BRPI0416240A (pt) 2003-11-05 2004-11-05 usos de um ou vários agonistas de famìlia de receptores de receptores de formil peptìdeo e semelhante a receptores de formil peptìdeo, composições farmecêuticas para evitar ou tratar infecções virais ou retro-virais, e, método para favorecer a resistência inata de hospedeiros a infecções virais

Country Status (14)

Country Link
US (1) US20070009926A1 (pt)
EP (1) EP1748789B1 (pt)
JP (1) JP2007516701A (pt)
AT (1) ATE493142T1 (pt)
AU (1) AU2004287205A1 (pt)
BR (1) BRPI0416240A (pt)
CA (1) CA2544972C (pt)
CY (1) CY1113088T1 (pt)
DE (1) DE602004030830D1 (pt)
DK (1) DK1748789T3 (pt)
PL (1) PL1748789T3 (pt)
PT (1) PT1748789E (pt)
WO (1) WO2005044292A2 (pt)
ZA (1) ZA200604550B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
US10545149B2 (en) * 2008-10-06 2020-01-28 Morehouse School Of Medicine Detection of HIV-related proteins in urine
GB201002409D0 (en) * 2010-02-12 2010-03-31 Univ Nottingham Methods
EP2618821A4 (en) 2010-09-24 2014-08-13 Brigham & Womens Hospital NANOSTRUCTURED GELS FOR CONTROLLED RELEASE OF CAPSUED MEDIUM
LT2970422T (lt) 2013-03-15 2018-06-25 F. Hoffmann-La Roche Ag Il-22 polipeptidai ir il-22 su fc sulieti baltymai bei panaudojimo būdai
WO2015054386A1 (en) 2013-10-08 2015-04-16 Georgia State University Research Foundation, Inc Compositions including il-18 and il-22 and their use in anti-viral therapies
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
WO2017181143A1 (en) 2016-04-15 2017-10-19 Generon (Shanghai) Corporation, Ltd. Use of il-22 in treating necrotizing enterocolitis
WO2020076453A1 (en) * 2018-10-11 2020-04-16 Alivio Therapeutics, Inc. Non-injectable hydrogel formulations for smart release

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010023070A1 (en) * 1998-05-29 2001-09-20 Reinhard Ebner Interleukins-21 and 22
JP2002516103A (ja) * 1998-05-29 2002-06-04 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド インターロイキン２１およびインターロイキン２２
US6939545B2 (en) * 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
US20030170823A1 (en) * 1999-12-23 2003-09-11 Presnell Scott R. Novel cytokine ZCYTO18
GB0024442D0 (en) * 2000-10-05 2000-11-22 Isis Innovation Genetic factors affecting the outcome of viral infections
AU2002240137A1 (en) * 2001-01-30 2002-08-12 University Of Iowa Research Foundation Antiviral activities of primate theta defensins and mammalian cathelicidins

Also Published As

Publication number Publication date
CA2544972A1 (en) 2005-05-19
ZA200604550B (en) 2008-04-30
WO2005044292A2 (en) 2005-05-19
EP1748789A2 (en) 2007-02-07
CA2544972C (en) 2013-04-23
AU2004287205A1 (en) 2005-05-19
PT1748789E (pt) 2011-04-04
JP2007516701A (ja) 2007-06-28
DK1748789T3 (da) 2012-01-23
PL1748789T3 (pl) 2011-09-30
DE602004030830D1 (de) 2011-02-10
WO2005044292A3 (en) 2006-11-23
EP1748789B1 (en) 2010-12-29
ATE493142T1 (de) 2011-01-15
CY1113088T1 (el) 2016-04-13
US20070009926A1 (en) 2007-01-11

Similar Documents

Publication Publication Date Title
CY1113088T1 (el) Il-22 για την προληψη λοιμωδων νοσηματων
BRPI0710232B8 (pt) composto antagonista do receptor de il-8, composição farmacêutica que compreende o dito composto e uso do mesmo para o tratamento de uma doença mediada por quimiocina
EA201071126A1 (ru) Антагонисты рецепторов глюкагона
CY1110856T1 (el) Ανταγωνιστες ιl-17a και il-17f και μεθοδοι χρησης αυτων
EA200970051A1 (ru) Антагонист рецептора il-8
WO2006052723A3 (en) G protein coupled receptor agonists and antagonists and methods of use
HRP20170530T1 (hr) Modulacija aktivnosti proneutrofina
WO2006137931A3 (en) Human monoclonal antibodies against hendra and nipah viruses
MX2007008017A (es) Polipeptidos que se ligan a br3 y usos de los mismos.
WO2007124423A3 (en) Il-8 receptor antagonists
NO20092470L (no) Substituerte diazepanforbindelser som orexinreseptorantagonister
WO2005113811A3 (en) Combinatorial selection of phosphorothioate aptamers for tgf-beta
CL2011000975A1 (es) Anticuerpo o fragmento del mismo que se une a al menos un residuo de animoacido del receptor tipo toll 3 (tlr3); composicion farmaceutica que lo comprende; su uso para tratar una condicion inflamatoria.
BRPI0620566B8 (pt) composição, composição para o tratamento profilático ou terapêutico de fibrose miocardial ou uma condição associada, composição para o tratamento profilático ou terapêutico de hipertensão, uso de uma composição, uso de vip ou de um fragmento do mesmo e uso de um vip
RU2010146161A (ru) Применение блокаторов интерферона типа i для профилактики и лечения псориаза
DE60230722D1 (de) Il-8-rezeptor-antagonisten
EA200200933A1 (ru) Антагонисты рецептора il-8
WO2020168151A3 (en) Quantitative mapping of chromatin associated proteins
WO2003002604A3 (en) G protein coupled receptors and dna sequences thereof
EA200900010A1 (ru) Замещенные 8-[6-амино-3-пиридил]ксантины
ATE519498T1 (de) Kombination aus somatostatin-analoga unterschiedlicher selektivität für humane somatostatin-rezeptor-subtypen
WO2002102839A3 (en) Novel g-protein coupled receptors and dna sequences thereof
WO2007062837A3 (en) Use of a 5-ht4 agonist for the treatment of irritable bowel syndrome characterized by mixed or alternating bowel habits
NO20025152D0 (no) EDG8-reseptor, dens fremstilling og anvendelse
WO2003018066A3 (en) A murine genomic polynucleotide sequence encoding a g-protein coupled receptor and methods of use therefor

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL